Full-Time

Director – Market Access

Posted on 12/6/2024

GeneDx

GeneDx

501-1,000 employees

Genetic testing for rare disease diagnostics

Biotechnology
Healthcare

Compensation Overview

$190k - $220kAnnually

Expert

Remote in USA

Category
Strategy Development
Business Development
Business & Strategy
Required Skills
Data Analysis

You match the following GeneDx's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • 10+ years of Market Access experience, preferably in molecular diagnostics
  • 5+ years of experience in genomics is strongly preferred
  • Demonstrated experience working with California payors, including IPAs
  • Bachelor’s degree or higher in related field
  • Proven track record of influencing payor medical policies
  • Strong executive presence with a solution-oriented mindset
  • Demonstrated ability to simplify and communicate complex information
  • Strong analytical, communication, and interpersonal skills
  • Highly adaptable in a rapidly changing environment
  • Ability to travel for business-critical meetings (up to 20% of the time)
Responsibilities
  • Develop innovative access, pricing, coverage and contracting strategies to support the needs of patients and their clinicians, that ultimately drive business growth, profitability and performance
  • Lead payor contracting strategy within the assigned geography/payors by identifying opportunities to obtain new contracts and/or improve rates and terms in existing contracts with regional payors, national payors, Managed Medicaid (MCOs), Lab Benefit Managers (LBMs), etc.
  • Drive the expansion of payor medical policies, conveying the latest evidence and guidelines to payor accounts, focusing on exome and genome sequencing
  • Collaborate with cross-functional teams, including Revenue Cycle Management (RCM), Legal, Training, Sales, and Marketing, aligning efforts for successful contract implementation
  • Guide the RCM team on changing payor requirements that may impact reimbursement success
  • Provide subject matter expertise in the following areas: professional society guidelines, health technology assessments, relevant published evidence, lab benefit management programs, medical policies, state legislation, and other regulations and market trends that may have business impact
  • Proactively share insights based on payor data and drive solutions to address opportunities to improve reimbursement success
  • Provide strategic Market Access guidance to the GeneDx field sales team within the assigned geography to achieve volume and revenue targets
  • Identify and develop opportunities for strategic payor partnerships that will further the GeneDx position as a market leader in genomics
  • Manage vendor relationships with the Market Access Team (e.g. DRG, Policy Reporter, etc.)
  • Establish partnerships with external stakeholders such as advocacy groups, health systems, state legislators, and key opinion leaders who may help accelerate policy change efforts
  • Serve as the payor-expert, advising internal business leads, based on your deep knowledge of the current and future payor landscape
  • Solve complex business problems on behalf of GeneDx, leveraging internal and external resources to devise effective solutions

GeneDx focuses on clinical genomics and rare disease diagnostics through genetic testing, analyzing DNA to identify mutations linked to health conditions. They have sequenced over 300,000 clinical patient exomes and provide rapid testing services, delivering results in as little as seven days. This quick turnaround is essential for timely diagnoses that can improve treatment outcomes. GeneDx aims to lead in clinical genomics by offering reliable genetic testing services that enhance patient care.

Company Size

501-1,000

Company Stage

IPO

Total Funding

$1.4B

Headquarters

Gaithersburg, Maryland

Founded

2000

Simplify Jobs

Simplify's Take

What believers are saying

  • Integration with Epic Aura accelerates diagnosis times and improves healthcare provider efficiency.
  • GeneDx Discover enhances drug discovery by providing access to over 700,000 exomes.
  • Calamos Advisors' $1.14 million investment indicates strong investor confidence in GeneDx.

What critics are saying

  • Increased competition from companies like Invitae and Illumina may impact market share.
  • Rapid technological advancements require continuous investment, straining financial resources.
  • Potential data privacy concerns could arise from using de-identified genetic data.

What makes GeneDx unique

  • GeneDx integrates with Epic Aura, streamlining genetic test ordering and reducing errors.
  • GeneDx Discover offers biopharmaceuticals access to a vast genetic dataset for drug development.
  • GeneDx's rapid exome sequencing delivers results in as little as seven days.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Unlimited Paid Time Off

401(k) Retirement Plan

Employee Discounts

Voluntary benefits

Company News

Stock Titan
Feb 12th, 2025
GeneDx to Participate in 45th Annual TD Cowen Health Care Conference

GAITHERSBURG, Md.-(BUSINESS WIRE)- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that company management will participate in the 45th Annual TD Cowen Health Care Conference from March 3-5 in Boston, MA.

Hit Consultant
Feb 10th, 2025
Genedx Launches On Epic Aura, Expanding Access To Genomic Testing

What You Should Know:– GeneDx, a leader in delivering improved health outcomes through genomic insights, today announced its launch on Epic Aura, a specialty diagnostics suite within Epic’s electronic health records (EHR).– The integration allows health systems to directly order GeneDx’s genetic tests, including exome sequencing (ES), whole genome sequencing (WGS), and rapid whole genome sequencing (rWGS), within their EHR systems.Enhanced Access to Genomic TestingThe integration with Epic Aura enables healthcare providers to seamlessly access GeneDx’s diagnostic services, streamlining the ordering process and accelerating the time to diagnosis for patients. By integrating with Epic Aura, health systems can now:Order GeneDx tests directly within their EHR: This eliminates the need for manual data entry and reduces the risk of errors.This eliminates the need for manual data entry and reduces the risk of errors. Receive results seamlessly: Results are automatically transmitted back to the EHR, ensuring timely access to patient information.Results are automatically transmitted back to the EHR, ensuring timely access to patient information. Improve efficiency and workflow: Streamline the diagnostic process and improve overall efficiency for clinicians.Unmatched Experience in Genomic TestingGeneDx has extensive experience in genomic testing, having sequenced over 750,000 exomes and genomes and collected millions of phenotypic data points. This vast dataset enables GeneDx to provide accurate and comprehensive diagnostic insights.Future Expansion PlansGeneDx plans to continue expanding its partnerships with health systems and integrating with other EHR platforms to further enhance access to genomic testing. The company is also committed to advancing its genomic technologies and expanding its offerings to address a wider range of genetic conditions.“GeneDx is committed to providing patient-centered solutions and our use of Aura simplifies the process for healthcare providers to ensure the first step to treatment, an accurate and fast genetic diagnosis, is easily accessible at a patient’s bedside and in the exam room,” said Katherine Stueland, President and CEO of GeneDx

Dataconomy
Jan 10th, 2025
The story of GeneDx (WGS) and its 2,434.65% stock surge in 2024

In early 2024, GeneDx announced enhancements to its Whole Genome Sequencing (WGS) product, aimed at accelerating diagnoses for patients with genetic conditions.

Hit Consultant
Nov 20th, 2024
Genedx Launches Ai Tool To Fuel Rare Disease Drug Discovery

What You Should Know:– GeneDx, a leader in genomic insights, has announced the launch of GeneDx Discover, a groundbreaking data visualization tool designed to revolutionize drug discovery and development.– The platform provides biopharmaceutical companies with access to de-identified and aggregated genetic data, empowering them to accelerate the development of new therapies.Addressing the Challenges of Drug DevelopmentThe traditional drug development process is lengthy, costly, and often unsuccessful. On average, it takes 12 years and $2.6 billion to bring a new drug to market, with a 90% failure rate. GeneDx Discover aims to address these challenges by leveraging the power of genetic data to improve decision-making and accelerate the development timeline.Unlocking the Potential of Genetic DataGeneDx Discover provides biopharmaceutical companies with:Access to a vast dataset: Leverages GeneDx’s industry-leading database of over 700,000 clinical exomes and genomes.Leverages GeneDx’s industry-leading database of over 700,000 clinical exomes and genomes. Self-service data exploration: Offers an easy-to-use interface for exploring and analyzing genetic data.Offers an easy-to-use interface for exploring and analyzing genetic data. Deeper understanding of patient populations: Provides insights into disease prevalence, phenotypic information, and variant-level details.Provides insights into disease prevalence, phenotypic information, and variant-level details. Enhanced decision-making: Enables data-driven decisions throughout the drug development process.Enables data-driven decisions throughout the drug development process

Hit Consultant
Nov 20th, 2024
Genedx Launches Tool To Fuel Rare Disease Drug Discovery

What You Should Know:– GeneDx, a leader in genomic insights, has announced the launch of GeneDx Discover, a groundbreaking data visualization tool designed to revolutionize drug discovery and development.– The platform provides biopharmaceutical companies with access to de-identified and aggregated genetic data, empowering them to accelerate the development of new therapies.Addressing the Challenges of Drug DevelopmentThe traditional drug development process is lengthy, costly, and often unsuccessful. On average, it takes 12 years and $2.6 billion to bring a new drug to market, with a 90% failure rate. GeneDx Discover aims to address these challenges by leveraging the power of genetic data to improve decision-making and accelerate the development timeline.Unlocking the Potential of Genetic DataGeneDx Discover provides biopharmaceutical companies with:Access to a vast dataset: Leverages GeneDx’s industry-leading database of over 700,000 clinical exomes and genomes.Leverages GeneDx’s industry-leading database of over 700,000 clinical exomes and genomes. Self-service data exploration: Offers an easy-to-use interface for exploring and analyzing genetic data.Offers an easy-to-use interface for exploring and analyzing genetic data. Deeper understanding of patient populations: Provides insights into disease prevalence, phenotypic information, and variant-level details.Provides insights into disease prevalence, phenotypic information, and variant-level details. Enhanced decision-making: Enables data-driven decisions throughout the drug development process.Enables data-driven decisions throughout the drug development process

INACTIVE